Envoy Medical (COCH) to Release Quarterly Earnings on Tuesday

Key Points

• Envoy Medical will report quarterly results on April 7 before the market opens; analysts expect ($0.24) EPS and $0.03M revenue after the company previously reported a ($0.26) EPS miss with $0.08M in revenue.
• Significant insider buying occurred on Feb. 12 — including 1,000,000 shares by Charles Brynelsen and 96,150 shares by Susan Kantor — and insiders acquired 20,433,650 shares worth $8.17M in the past 90 days, now owning 5.70% of the company.
• The stock trades around $0.64 with a $49.4M market cap and a one‑year range of $0.36–$1.91, while Wall Street consensus is a Hold with a $9.50 target despite only two analyst ratings and a recent Weiss Ratings "sell (e+)" note.

Envoy Medical (NASDAQ:COCH - Get Free Report) is anticipated to issue its results before the market opens on Tuesday, April 7th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $0.03 million for the quarter.

Envoy Medical (NASDAQ:COCH - Get Free Report) last announced its earnings results on Monday, March 23rd. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect Envoy Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Envoy Medical Price Performance

NASDAQ COCH opened at $0.64 on Tuesday. The stock's 50 day simple moving average is $0.68 and its 200 day simple moving average is $0.77. Envoy Medical has a one year low of $0.36 and a one year high of $1.91. The firm has a market cap of $49.43 million, a PE ratio of -0.53 and a beta of 2.08.

Insider Transactions at Envoy Medical

In related news, Director Susan Kantor bought 96,150 shares of the company's stock in a transaction on Thursday, February 12th. The stock was bought at an average cost of $0.40 per share, with a total value of $38,460.00. Following the completion of the purchase, the director owned 174,037 shares in the company, valued at approximately $69,614.80. The trade was a 123.45% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Charles Brynelsen bought 1,000,000 shares of Envoy Medical stock in a transaction dated Thursday, February 12th. The shares were bought at an average price of $0.40 per share, for a total transaction of $400,000.00. Following the completion of the transaction, the director directly owned 1,050,000 shares of the company's stock, valued at $420,000. This represents a 2,000.00% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have acquired 20,433,650 shares of company stock worth $8,173,460. Corporate insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. CIBC Bancorp USA Inc. bought a new position in Envoy Medical in the 3rd quarter valued at $60,000. Geode Capital Management LLC increased its stake in shares of Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company's stock valued at $65,000 after buying an additional 51,813 shares during the period. Finally, Focus Partners Wealth bought a new stake in shares of Envoy Medical during the first quarter worth $276,000. Institutional investors and hedge funds own 8.59% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Envoy Medical in a research note on Tuesday, January 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $9.50.

Envoy Medical Company Profile

Envoy Medical NASDAQ: COCH is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company's lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical's flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.